Identity
- Security key
- 11181
- Ticker
- ABEO
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 1980-09-19
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- ABEO
Detail
Enriched 2026-08-14 20:47
- Market cap
- $425,183,774.24
- Shares outstanding (class)
- 56,995,144
- Shares outstanding (weighted)
- 56,995,144
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 226
- Location
- CLEVELAND, OH
- Description
Abeona Therapeutics Inc is a commercial-stage biopharmaceutical company. The company is focused on developing cell and gene therapies for life-threatening diseases. The company's ZEVASKYN (prademagene zamikeracel) is an autologous cell-based gene therapy for the treatment of wounds in adults and pediatric patients with recessive dystrophic epidermolysis bullosa (RDEB). The company's development portfolio includes adeno-associated virus (AAV)-based gene therapies for ophthalmic diseases with high unmet medical need.